148 related articles for article (PubMed ID: 37955298)
1. [Pneumococcal vaccination among at-risk groups with comorbidities : guidelines from the "Belgian Superior Health Council" and reimbursement criteria].
Scheen A; Louis R; Lancellotti P; Jouret F; Delwaide J; Moutschen M
Rev Med Liege; 2023 Nov; 78(11):665-673. PubMed ID: 37955298
[TBL] [Abstract][Full Text] [Related]
2. [Apexxnar®, 20-valent pneumococcal conjugate vaccine].
Scheen AJ; Louis R; Moutschen M
Rev Med Liege; 2022 Nov; 77(11):678-683. PubMed ID: 36354231
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.
Marbaix S; Mignon A; Taelman A; Averin A; Atwood M; Vietri J
Expert Rev Vaccines; 2023; 22(1):1008-1021. PubMed ID: 37872765
[TBL] [Abstract][Full Text] [Related]
4. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
Shirley M
Drugs; 2022 Jun; 82(9):989-999. PubMed ID: 35793027
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection.
Marbaix S; Peetermans WE; Verhaegen J; Annemans L; Sato R; Mignon A; Atwood M; Weycker D
PLoS One; 2018; 13(7):e0199427. PubMed ID: 29979689
[TBL] [Abstract][Full Text] [Related]
6. 20‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval.
Shirley M
Paediatr Drugs; 2023 Sep; 25(5):613-619. PubMed ID: 37440125
[TBL] [Abstract][Full Text] [Related]
7. The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value.
Janssens E; Flamaing J; Vandermeulen C; Peetermans WE; Desmet S; De Munter P
Acta Clin Belg; 2023 Feb; 78(1):78-86. PubMed ID: 35171752
[TBL] [Abstract][Full Text] [Related]
8. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
9. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
Weil-Olivier C; van der Linden M; de Schutter I; Dagan R; Mantovani L
BMC Infect Dis; 2012 Sep; 12():207. PubMed ID: 22954038
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease.
Kopp A; Mangin O; Gantzer L; Lekens B; Simoneau G; Ravelomanantsoa M; Evans J; Bergmann JF; Sellier P
Hum Vaccin Immunother; 2021 Jan; 17(1):162-169. PubMed ID: 32429734
[No Abstract] [Full Text] [Related]
11. Prevention of pneumococcal disease: an update on the Belgian Consensus Report.
Peleman RA; Peetermans WE; Van Laethem Y; Bachez PG; Vanatoru J; Van Wassenhove K; Struelens MJ; Verhaegen JL
Acta Clin Belg; 1999 Dec; 54(6):321-7. PubMed ID: 10686704
[TBL] [Abstract][Full Text] [Related]
12. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal vaccination-A literature review and practice guideline update.
El-Beyrouty C; Buckler R; Mitchell M; Phillips S; Groome S
Pharmacotherapy; 2022 Sep; 42(9):724-740. PubMed ID: 35876213
[TBL] [Abstract][Full Text] [Related]
14. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.
Yildirim I; Shea KM; Little BA; Silverio AL; Pelton SI;
Pediatrics; 2015 Mar; 135(3):495-503. PubMed ID: 25647674
[TBL] [Abstract][Full Text] [Related]
15. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
[TBL] [Abstract][Full Text] [Related]
16. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
Vaccine; 2023 Aug; 41(38):5662-5669. PubMed ID: 37544825
[TBL] [Abstract][Full Text] [Related]
17. New Pneumococcal Vaccines for Prevention of Invasive Pneumococcal Disease in Adult Patients With Inflammatory Bowel Disease.
Crosby S; Schuh MJ; Becker M; Ivanov M; Caldera F; Farraye FA
Inflamm Bowel Dis; 2023 Apr; 29(4):661-664. PubMed ID: 35830419
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].
Ludwig E; Mészner Z;
Orv Hetil; 2014 Dec; 155(50):1996-2004. PubMed ID: 25481502
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal infection in adults: burden of disease.
Drijkoningen JJ; Rohde GG
Clin Microbiol Infect; 2014 May; 20 Suppl 5():45-51. PubMed ID: 24313448
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany.
Kühne F; Achtert K; Püschner F; Urbanski-Rini D; Schiller J; Mahar E; Friedrich J; Atwood M; Sprenger R; Vietri J; von Eiff C; Theilacker C
Expert Rev Vaccines; 2023; 22(1):921-932. PubMed ID: 37881844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
